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Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder with cholestasis as a defining clinical fea-
ture. We sought to characterize hepatic outcomes in a molecularly defined cohort of children with ALGS-related chol-
estasis. Two hundred and ninety-three participants with ALGS with native liver were enrolled. Participants entered the 
study at different ages and data were collected retrospectively prior to enrollment, and prospectively during the study 
course. Genetic analysis in 206 revealed JAGGED1 mutations in 91% and NOTCH2 mutations in 4%. Growth was 
impaired with mean height and weight z-scores of <−1.0 at all ages. Regression analysis revealed that every 10  mg/dL 
increase in total bilirubin was associated with a decrease in height z-score by 0.10 (P  =  0.03) and weight z-score by 
0.15 (P  =  0.007). Total bilirubin was higher for younger participants (P  =  0.03) with a median of 6.9 mg/dL for those 
less than 1 year old compared with a median of 1.3 mg/dL for participants 13 years or older. The median gamma glu-
tamyl transferase also dropped from 612 to 268 in the same age groups. After adjusting for age, there was substantial 
within-individual variation of alanine aminotransferase. By 20 years of age, 40% of participants had developed definite 
portal hypertension. Estimated liver transplant–free survival at the age of 18.5 years was 24%. Conclusions: This is the 
largest multicenter natural history study of cholestasis in ALGS, demonstrating a previously underappreciated burden 
of liver disease with early profound cholestasis, a second wave of portal hypertension later in childhood, and less than 
25% of patients reaching young adulthood with their native liver. These findings will promote optimization of ALGS 
management and development of clinically relevant endpoints for future therapeutic trials. (Hepatology Communications 
2020;4:387-398).
Alagille syndrome (ALGS) is an autosomal dominant, multisystem disorder with highly variable clinical features.(1-4) Mutations in 
JAGGED1 (JAG1) are identified in more than 90% of 
clinically defined patients with ALGS, and NOTCH2 
mutations have been reported in a small minority.(5-8) 
Cholestasis is a key clinical defining feature, and 
ALGS is, in fact, the most common cause of  inherited 
cholestasis in children.(9) Current knowledge of the 
characteristics and outcomes of cholestasis in ALGS 
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is based on retrospective single-center studies from 
more than 15 years ago.(4,10,11) These studies suffer 
from a lack of consistent clinical and molecular defi-
nitions of ALGS and may be reporting on patients 
with other causes of cholestasis or on siblings with 
milder ALGS phenotypes. In addition, these older 
studies include a spectrum of individuals ranging from 
severe cholestasis to minimal hepatic manifestations. 
Based on these heterogeneous and loosely classified 
data, liver involvement in ALGS has been regarded as 
having a relatively good prognosis, with only approxi-
mately 20%-30% of patients requiring liver transplan-
tation.(10,11) There is a paucity of data regarding the 
frequency of hepatic complications in ALGS, espe-
cially in the current era.
The goal of this study was to characterize the bur-
den and natural history of liver disease in children with 
ALGS-related cholestasis within a large, ongoing, mul-
ticentered study of childhood cholestatic liver diseases. 
We sought to determine the frequency of hepatic com-
plications, examine transplant-free survival, and explore 
the determinants of growth impairment in ALGS. It is 
imperative to better understand the natural history of 
cholestasis in ALGS in order to optimize management 
strategies, such as the timing of liver transplantation, to 
provide improved prognostic information for patients 
and their families, and to design clinical trials to evalu-
ate novel therapies for this disorder.
Methods
stuDy Design anD 
paRtiCipants
This is a longitudinal study of hepatic disease pro-
gression in a prevalent cohort of patients with ALGS, all 
of whom had cholestasis. Participants entered the study 
at different ages, and data were collected retrospectively 
prior to enrollment, and prospectively during the study 
course (Fig. 1). Participants included in this study were 
enrolled in the Longitudinal Study of Genetic Causes 
View this article online at wileyonlinelibrary.com.
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of Intrahepatic Cholestasis (LOGIC; NCT00571272) 
protocol organized within the Childhood Liver Disease 
Research Network (ChiLDReN), a National Institute of 
Diabetes and Digestive and Kidney Diseases/National 
Institutes of Health–funded network of 14 pediatric 
academic medical centers across North America. This 
study was approved by institutional review boards at 
each center, and informed consent was obtained from 
parents/guardians or participants 18 years or older, and 
assent from children of appropriate age.
LOGIC is a longitudinal observational study of 
the natural history of several genetic causes of intra-
hepatic cholestasis, including ALGS. Defined data 
elements are collected systematically and prospec-
tively at yearly intervals for up to 20 years, or until 
death, liver transplant, or dropout (Fig. 1). Pertinent 
data are recorded about past history at enrollment, 
and interval medical history is collected annually, 
including surgery and major events or complications 
such as ascites, bone fractures, and gastrointestinal 
bleeding. Growth parameters and standard laboratory 
evaluations are recorded at enrollment and annually at 
follow-up visits. This data analysis focuses on natural 
history prior to liver transplantation.
All participants with ALGS in LOGIC were less 
than 25  years of age at enrollment, had confirmed 
ALGS by set diagnostic clinical criteria (Supporting 
Table S1), and had evidence of cholestasis. Only 
probands were included (no affected siblings). For 
the purposes of this study, LOGIC cholestasis 
enrollment criteria were defined by the presence of 
one or more of the following: fasting total serum 
bile acid greater than 3 times the upper limit of nor-
mal for age, direct/conjugated bilirubin greater than 
2  mg/dL, fat-soluble vitamin deficiency otherwise 
unexplainable, gamma-glutamyl transferase (GGT) 
greater than 3 times the upper limit of normal for 
age, and/or intractable pruritus explainable only by 
liver disease. The onset of definite clinically evident 
portal hypertension in this cohort was assessed using 
the following criteria, which have recently been 
published by the ChiLDReN(12): (1) ascites and the 
use of diuretics, or (2) documented esophageal or 
gastric varices on endoscopy, or (3) presence of both 
Fig. 1. Schematic to represent study design. This schematic illustrates the time of study entry, time to complication event, time to liver 
transplant or death, and the censoring of six classes of example subjects. The solid black dot represents the onset of cholestasis. The horizontal 
dotted lines indicate the time period prior to study entry. The white circle represents the time of study enrollment. The red “x” represents 
the time of complication event (e.g., bone fracture). The black and white squares represent the time of liver transplant/death and censoring, 
respectively. Although example participants A, B, C, and D were enrolled and observed in the LOGIC study at various time points after birth, 
the subjects in groups E and F experienced liver transplant/death before the opportunity to be enrolled, and therefore were not observed in 
the study. In addition, not all events were observed in A, B, C, and D due to right censoring and left censoring. For example, the event time of 
complication was censored by liver transplant/death for participant A. Participant B experienced the complication event before liver transplant/
death. Subject C experienced the complication event before being enrolled, and the time of the complication event was retrospectively collected. 
For subject D, the complication did not happen before he or she was censored (dropped out of the LOGIC study or the data were cut off to 
retrieve the analysis data set). Abbreviation: LOGIC, Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis.
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splenomegaly (spleen palpable > 2  cm below cos-
tal margin) and platelets < 150,000/mm3. Pruritus 
was documented using the clinician scratch scale 
(CSS), which is a physician-observed assessment 
tool devised by Whitington.(13) The CSS scores the 
physical manifestations of pruritus as follows: 0 = 
none, 1 = rubbing or mild scratching when undis-
tracted, 2 = active scratching without evident skin 
abrasions, 3 = abrasions evident, and 4 = cutaneous 
mutilation, hemorrhage, and scarring evident.
Participants were confirmed as ALGS by stan-
dard clinical criteria and/or the presence of a disease- 
causing mutation in JAG1 or NOTCH2. The clini-
cal criteria were at least three of the following: bile 
duct paucity on liver biopsy, heart murmur, or cardiac 
anomaly; posterior embryotoxon or other anterior 
chamber defect; butterfly vertebrae; and/or character-
istic facial features and renal anomalies. The details 
of the inclusion criteria are described in Supporting 
Table 1. At the time of data analysis, the total num-
ber of patients with ALGS in LOGIC was 377. 
Participants with a liver transplant prior to enrollment 
were excluded (n = 74) from this analysis of pretrans-
plant natural history, and an additional 10 participants 
were excluded for having a non-ALGS gene mutation 
(ABCB4, ABCB11, or HNF1beta), resulting in a sam-
ple of 293 participants with ALGS.
statistiCal analysis
Summary statistics were calculated for baseline par-
ticipant characteristics. Graphs of laboratory values col-
lected longitudinally over the course of the study were 
plotted by participant age. A statistical challenge for 
analyzing this data set is left-truncated survival data, 
due to the prevalent cohort study design. For studying 
rare diseases, a prevalent cohort design allows faster 
enrollment and is more feasible than an incident cohort 
design. However, because the LOGIC study enrolls 
patients with ALGS at any age, a subset of our target 
population (a representative population of all patients 
with ALGS-related cholestasis) was not captured due 
to the occurrence of liver transplant or death before 
being encountered by this study. We therefore ascer-
tained a select cohort that was potentially healthier 
than our actual target population. In all survival anal-
yses, age was used as the time variable, and appropriate 
statistical methods were used to adjust for left trunca-
tion so that all estimates derived referred to our target 
population, namely, all patients with ALGS-related 
cholestasis rather than the observed prevalent cohort. 
We calculated the transplant-free survival and cumu-
lative incidence functions for transplant-free survival 
(transplant or death before transplant, whichever hap-
pened first), accounting for left truncation. To calculate 
cumulative incidence rates over age for ascites, bone 
fracture, and variceal bleeding, the methods of Wang(14) 
and Peng and Fine(15) for nonparametric estimation 
with left-truncated semicompeting risk data were 
used, treating liver transplant and death as competing 
risk events. When the method of Peng and Fine was 
applied, a bootstrapping method was used to calculate 
taBle 1. CHaRaCteRistiCs at Baseline oF 
paRtiCipants WitH algs
Characteristic Group or Statistic
Age (years) n 293
Median (Q1, Q3) 3.0 (1.0-8.0)
Range (min, max) (0, 25)
Gender Male 175 (60%)
Mutational analysis JAG1 187 (64%)
NOTCH2 9 (3%)
Neither JAG1 or 
NOTCH2
10 (3%)
Not tested 87 (30%)
Race White 181 (62%)





Missing or refused 27 (9%)
Ethnicity Hispanic 65 (22%)
Non-Hispanic 219 (75%)
Missing or refused 9 (3%)
Cardiac features Severe* heart defect 89 (30%)
Mild† heart defect 170 (58%)
No cardiac involvement 34 (12%)
Renal features Any renal anomaly 63 (22%)
Height z-score n 266
Mean (SD) −1.9 (1.4)
Weight z-score n 269
Mean (SD) −1.9 (1.5)
BMI z-score‡ n 171
Mean (SD) −0.4 (1.2)
*Severe heart defect = any intracardiac or valvar defect, coarctation 
of the aorta.
†Mild heart defect = peripheral pulmonary stenosis, murmur with 
normal echocardiogram.
‡Not available for participants younger than 2 years old.
Abbreviation: BMI, body mass index.
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95% confidence intervals (CIs) for the cumulative 
incidence rates for these complications. To study the 
impact of cholestasis, the presence of a cardiac defect 
or renal anomaly on growth, we conducted a growth 
curve analysis using a linear mixed-effects model to 
repeated measures of height z-score with total bilirubin 
as time-dependent covariate and cardiac defect/renal 
anomaly as a time-independent covariate. For this anal-
ysis, we used time from study entry as the time variable. 
To study laboratory markers and symptoms of cholesta-
sis among survivors over time, we calculated the medi-
ans and interquartile range and examined their changes 
over age visually. In addition, we used generalized 
estimation equations to test whether median or mean 
levels changed significantly over age for each of the lab-
oratory markers among study participants, assuming a 
linear relationship between median level and age.
Results
Between December 2007 and September 2018, 293 
participants with ALGS meeting the enrollment cri-
teria (mean age of 5 years; range: 2 weeks to 25 years) 
were enrolled and prospectively followed. The median 
duration of follow-up was 2.7 years (range 0-10 years). 
The duration of follow-up was similar across different 
ages in the study cohort. Baseline characteristics of the 
293 participants with ALGS are included in Table 1. 
All participants had cholestasis, as specified by the 
inclusion criteria. Eighty-eight percent of the cohort 
had a cardiac or cardiovascular anomaly and 22% had a 
renal anomaly, in keeping with other series of patients 
with ALGS.(10,16) Additional details regarding the 
ALGS disease characteristics are presented in Table 2.
genetiCs
Mutational analysis was available in 206 of 293 par-
ticipants, revealing mutations in JAG1 in 91% and in 
NOTCH2 in 4% of those tested. No mutation in JAG1 
or NOTCH2 was identified in 5% of participants, even 
though they met strict diagnostic clinical criteria, as 
described previously. The types of mutation identi-
fied in this cohort (Table 3) reflected the published 
data, with a preponderance of protein-truncating 
mutations.(17,18) An analysis of genotype–phenotype 
relationships was unrevealing for JAG1. There was 
no impact of JAG1 mutation type on transplant-free 
survival (P  =  0.11) in this cohort, nor on severity of 
cardiac defect (P  = 0.34). No analysis was performed 
on the NOTCH2 genotypes and phenotype due to the 
small numbers of patients with these mutations.
gRoWtH
Growth was impaired in participants with ALGS 
at enrollment (Table 1). Mean height and weight 
z-scores were lower than −1 at all ages in the study 
population (Supporting Table S2).
taBle 2. FeatuRes oF algs at enRollment
Disease Features n Count (%)
Cardiac
Peripheral pulmonary stenosis 263 194 (74%)
Pulmonary valve stenosis 247 34 (13%)
Tetralogy of fallot 251 16 (6%)
Ventricular septal defect 249 33 (13%)
Atrial septal defect 246 32 (13%)
Other cardiac anomaly 276 92 (33%)
Facies
Deep-set eyes 265 209 (79%)
Broad forehead 273 240 (88%)
Pointed chin 269 238 (88%)
Eyes
Posterior embryotoxon 263 114 (43%)
Axenfeld’s anomaly 244 3 (1%)
Other eye condition 260 15 (6%)
Skeletal
Butterfly vertebrae 268 104 (39%)
Other skeletal condition 269 11 (4%)
Renal
Dysplastic kidney 265 10 (4%)
Single kidney 264 3 (1%)
Renal tubular acidosis 261 24 (9%)
Other renal structural anomaly 264 34 (13%)
taBle 3. ClassiFiCation oF JAG1 anD NOTCH2 
mutations iDentiFieD in tHe stuDy CoHoRt 
(n = 196)
Classification JAG1 (n = 187) NOTCH2 (n = 9)
Insertion/deletion 70 (37%) 2 (22%)
Missense 35 (19%) 5 (56%)
Nonsense 48 (26%) 1 (11%)
Splice site 18 (10%)
Whole/partial gene deletion 4 (2%)
Other 11 (6%)
Missing 1 (1%) 1 (11%)
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A growth curve analysis, adjusted for the presence of 
a cardiac defect and age at enrollment, demonstrated the 
impact of total bilirubin (TB) on growth. This model 
shows that every 10 mg/dL increase in TB was associ-
ated with a decrease in height z-score by 0.10 (P = 0.03) 
and a decrease in weight z-score by 0.15 (P  =  0.007). 
The same model was used to assess the impact of any 
cardiac defect on growth in ALGS. After adjusting for 
TB and age at enrollment, the presence of a severe car-
diac defect was not associated with either height z-score 
(P = 0.15) nor weight z-score (P = 0.32).
HeaRing assessment
Audiology testing was performed in 110 patients 
with ALGS. Of these, 62 (56%) passed air conduc-
tion testing in both ears at all frequencies, 42 (38%) 
failed at least one frequency in at least one ear, and 
6 (5%) were inconclusive due to missing tests. Those 
who failed air conduction then went on to have tym-
panometry testing. Eleven of 42 (26%) passed both 
ears and 28 of 42 (67%) failed one or both ears. In 2 
of 42 tympanometry was not performed, and in 1 of 
42 the data were not interpretable due to ear tubes.
natuRal HistoRy anD 
outComes oF liVeR 
inVolVement
In this ALGS cohort, 10 of 293 (3%) had under-
gone Kasai portoenterostomy in infancy. Twenty-
nine (10%) participants had a partial biliary diversion 
procedure either before enrollment or during follow 
up.
Serial biochemistry and hematologic parameters 
were recorded for all participants during follow-up 
(Fig. 2). TB was higher for younger participants 
(P  =  0.03), with a median of 6.9  mg/dL for those 
less than 1 year old, and was lower with a median 
of 1.3  mg/dL for participants 13 years or older sur-
viving with their native liver. This was mirrored by a 
fall in median total cholesterol (P  <  0.001) (Fig. 2). 
The median level of GGT was also higher in the 
younger participants (P = 0.002), with a median of 612 
for those younger than 1 year old, and a median of 
268 for participants 13 years or older surviving with 
their native liver. The change in median alanine ami-
notransferase (ALT) and aspartate aminotransferase 
(AST) with age reached statistical significance (Fig. 1); 
however, these changes represented a small drop in 
clinical terms, as the median ALT was 154 in those 
younger than 1 year old and 131 in participants aged 
13 or older, and the median AST fell from 176 to 116 
in the same age groups. After adjusting for age, the 
biological variation of ALT within an individual was 
noted to be quite large. The SD of the variation of the 
log10 base–transformed ALT was approximately 0.18, 
which means that ALT can vary from 56% lower to 
129% higher for 95% of the time in a given individual.
Platelet count was higher for younger participants 
(P  < 0.001) (Fig. 2), with a median of 395,000/mL 
for those younger than 1 year old, and it was lower for 
participants aged 13 years or older surviving with their 
native liver, with a median of 177,000/mL. The interna-
tional normalized ratio varied very little with age in this 
population, and the median value was 1.0 across all ages.
The improvement in biochemical markers of 
cholestasis among survivors with native livers over time 
was accompanied by a reduction in the prevalence of 
pruritus and xanthomas by age in this cohort (Fig. 3). 
Pruritus was recorded on an annual basis using the 
CSS.(13) The highest percentage of participants with 
ALGS with pruritus occurred in those 2 years of age 
and tended to be lower for older participants. The prev-
alence of xanthomas among survivors in the cohort also 
declined with age, with no participants having extensive 
xanthomas after the age of 12 years. The frequency of 
xanthomas was highest among participants aged 2 years.
The risk of hepatic complications was carefully 
assessed in the cohort (Fig. 4), accounting for left trun-
cation in the study sample. Among patients with ALGS-
related cholestasis, the estimated cumulative incidence of 
ascites at the age of 20 years was 36% (95% CI: 16%, 
57%). Thirty-seven participants reported to have devel-
oped their first episode of ascites prior to study enroll-
ment, and another 36 did so during follow-up. One or 
more episodes of gastrointestinal bleeding were reported 
to have occurred in 23 patients prior to enrollment and 
17 during the study period, which corresponded to a 16% 
(95% CI: 4%, 28%) cumulative incidence of first gastro-
intestinal bleeding in participants with ALGS-related 
cholestasis. Splenomegaly was reported in 62 patients 
prior to study enrollment and another 49 during follow- 
up. Thrombocytopenia (platelet count < 150,000/mL) 
was present in 29 patients prior to enrollment and 45 
developed it during follow-up for a cumulative incidence 
of 33% (95% CI: 15%, 50%). The estimated cumulative 
incidence of splenomegaly was 50% (95% CI: 39%, 
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59%) by 20 years of age. By 20 years of age, 40% (95% 
CI: 20%, 60%) of patients developed definite clinically 
evident portal hypertension.
Finally, 44 of the participants with ALGS 
reported to have experienced a bone fracture prior 
to study enrollment and another 27 thereafter; the 
estimated cumulative incidence of fracture by age of 
20 years was 26% (95% CI: 17%, 55%). Interestingly, 
most fractures occurred in younger children, with 67 
of the 71 reported events occurring before the age 
of 13 years.
suRViVal
Figure 5 represents a survival curve of this cohort 
with ALGS-related cholestasis. Fifty-eight partici-
pants had liver transplant and 11 died with native liver 
during the study follow-up. Estimated transplant-free 
survival at the age of 18.5 years was 24% (95% CI: 
16%, 36%). There was no center effect impacting the 
rate of transplant-free survival (P = 0.38).
Among the 11 participants who died with native 
liver during the study, only three deaths were directly 
Fig. 2. Laboratory characteristics among survivors by age. Individual participant laboratory values are shown over time with the median 
and interquartile range shown in blue and P values. The P values are from tests for trends in laboratory values by age in generalized 
estimating equation models accounting for correlation among repeated measures within participants. Serum bilirubin, cholesterol, and 
GGT are higher earlier in life but improve in many children. The platelet count progressively falls over childhood. Due to sparse data after 
age 20 years, only laboratory values measured at age 20 or younger are presented. Abbreviations: GGTP, gamma-glutamyl transpeptidase; 
and IQR, interquartile range.
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attributable to liver disease. The remainder were due 
to cardiac involvement, pulmonary hemorrhage, and 
“other” (Supporting Table S3).
Discussion
This large, multicenter, natural history study of 
patients with ALGS, who presented with cholesta-
sis, demonstrates a previously underappreciated 
burden of liver disease. Prior studies have included 
participants with ALGS with heterogeneous clini-
cal features(10,11,19); our study characterizes a cohort 
of rigorously defined children with ALGS, all of 
whom have cholestasis, and therefore represents a 
focused assessment of the outcomes of liver disease 
in ALGS. In this cohort, survival to early adulthood 
with native liver occurred in only 24% of children 
at 18.5 years. As expected, clinical manifestations of 
cholestasis (pruritus and xanthomas) were prevalent 
in early childhood and improved in transplant-free 
survivors after the age of 5 years. Given the prev-
alent nature of our study population, this change 
could be due to spontaneous improvement and/or 
survival selection. Spontaneous improvement in 
cholestasis has been described previously in early 
childhood in ALGS and led to the supposition that 
only 20%-30% of individuals with ALGS require 
liver transplantation.(10,20) However, here we identify 
a “second wave” of hepatic disease in later childhood 
in ALGS with the development of portal hyper-
tension, despite improvement of cholestasis. This 
Fig. 3. Prevalence of pruritus and xanthoma among survivors by age. Pruritus, as measured by CSS, and the burden of xanthomas improve 
over time in ALGS survivors with native livers. CSS scores the physical manifestations of pruritus as follows: 0 = none, 1 = rubbing or 
mild scratching when undistracted, 2 = active scratching without evident skin abrasions, 3 = abrasion evident, 4 = cutaneous mutilation, 
hemorrhage, and scarring evident.
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Fig. 4. Cumulative incidence of hepatic complications and portal hypertension. The cumulative incidence of ascites, splenomegaly, and 
thrombocytopenia increase with age, resulting in an increase in the onset of definite clinically evident portal hypertension as defined by 
(1) ascites treated by diuretics, (2) presence of esophageal or gastric varices, or (3) both splenomegaly (spleen palpable > 2 cm below costal 
margin) and fewer than 150,000/mm3 platelets. Abbreviation: PHT, portal hypertension.
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portal hypertensive phase is associated with clini-
cally impactful complications (such as ascites) and 
the need for liver transplantation later in childhood.
Laboratory parameters reflected this clinical pattern 
of liver disease evolution in ALGS. Serum total and 
conjugated bilirubin and cholesterol were higher ear-
lier in life but improved in many children who did not 
undergo liver transplant. In contrast, the platelet count 
progressively fell in survivors through childhood. Of 
note, although serum transaminases did not change 
over time in a clinically meaningful way in the entire 
cohort, we did identify tremendous intrapatient ALT 
variation in patients with ALGS-related cholestasis. 
Further studies are needed with more frequently col-
lected laboratory data to better capture and character-
ize this variation in serum transaminases in individual 
patients with ALGS. This will be crucial to the design 
of clinical trials for new therapies targeting ALGS.
Growth failure has been widely reported in 
ALGS,(21,22) and multiple proposed mechanisms have 
included growth hormone insensitivity and subopti-
mal nutrition.(23,24) In this cohort, the clinical deter-
minants of growth impairment in ALGS were not 
easily identified. Total bilirubin had a modest neg-
ative effect on height and weight z-scores, and the 
potential effect of a significant cardiac defect was not 
statistically significant. This suggests that the growth 
impairments in ALGS may be intrinsic and related to 
the underlying genetic defects, rather than to second-
ary manifestations of clinical disease in the liver or 
heart. These data are somewhat surprising, especially 
when it has been shown previously that children with 
ALGS who undergo liver transplantation demonstrate 
a larger degree of catch-up growth compared with 
matched biliary atresia counterparts, suggesting that 
correction of cholestasis ameliorates growth impair-
ments even more so in ALGS than biliary atresia.(25) 
It is possible that the effects of cholestasis on growth 
could not be fully explored in this cohort, as all par-
ticipants were ascertained on the basis of cholestasis. 
These data also further underscore the need for an 
ALGS-specific growth chart, so we can understand 
the growth patterns and better interpret the impact of 
liver transplantation or new medications.
Bone fractures were common in this cohort, as has 
been noted in ALGS previously.(26) Most of these 
occurred early, before the age of 13 years. It is diffi-
cult to attribute this clustering of fractures to the more 
profound cholestasis that is seen in the first few years 
of life in ALGS, as by the age of 13 years the median 
TB had fallen considerably in this cohort. Although 
chronic cholestatic liver disease may predispose one 
to poor bone health related to malabsorption and fat- 
soluble vitamin deficiencies, it has also been proposed 
that the direct effects of decreased Notch signaling in 
bone may be contributing. This is supported by a recent 
study from ChiLDReN, in which 49 patients with 
ALGS and 99 children with other inherited chronic liver 
diseases underwent dual energy X-ray absorptiometry 
(DXA) scans.(27) In ALGS, DXA measures were found 
Fig. 5. Transplant-free survival in ALGS. The method for calculating survival accounted for left truncation and estimated the transplant-
free survival at the age of 18.5 years as 24% (95% CI: 16%, 36%). There was no liver or transplant/death observed at age 20 or older in this 
cohort. The estimated survival curve was truncated at the age of 20 years.
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to be low, but improved after adjustment for weight and 
height. Of note, DXA z-scores in the ALGS popula-
tion correlated negatively with measures of cholestasis, 
including TB and serum bile acid levels. These data sup-
port multifactorial influences on bone density in ALGS, 
with possible contribution of impaired Notch signaling.
Although chronic otitis media(4,20) and hearing 
loss(20) have been noted in ALGS previously, here 
we present the largest set of audiology testing in this 
population. It is clear that hearing loss is common in 
ALGS and that many of these patients have some 
evidence of middle ear pathology on tympanometry. 
Continued prospective follow-up of this cohort will be 
needed to determine whether these findings persist or 
resolve over time and the true prevalence of sensori-
neural hearing loss in ALGS. Further characterization 
of hearing loss in ALGS is necessary to explore the 
etiology; recurrent otitis media related to underlying 
craniofacial anomalies have been cited as one possible 
cause as well as defects of the middle ear bones.(28) 
These data suggest that tympanometry, at a minimum, 
should be included as routine surveillance in ALGS.
There are several limitations to this study. Patients 
were enrolled at different ages, and data before study 
enrollment were retrospectively collected and there-
fore likely less reliable. This also led to a wide varia-
tion in the duration of follow-up. Mutational analysis 
was not available for the entire cohort, although the 
strict clinical diagnostic criteria were carefully applied 
at each center to compensate for these missing genetic 
data. Finally, it could be argued that there was an 
ascertainment bias, as all participants were enrolled 
at tertiary-level liver centers and therefore the pop-
ulation was enriched with more severe ALGS liver 
disease. Despite this, the primary objective of the 
study to characterize liver disease in participants with 
ALGS-related cholestasis was fulfilled. The intent 
was not to determine outcomes in all patients with 
ALGS but to study a carefully selected cohort with 
ALGS-related cholestasis.
In conclusion, this study represents a comprehen-
sive assessment of liver disease in a carefully defined 
population of children with ALGS in the current era. 
Specifically, we highlight a previously underrecognized 
and high burden of progressive liver disease in choles-
tatic ALGS manifested first by pruritus, xanthomas, 
and fractures during toddlerhood, with a second wave 
of portal hypertension and associated complications 
later in adolescence. Together, this burden of liver 
disease results in a high rate of liver transplantation in 
those presenting with cholestasis, such that less than 
25% of children with ALGS-related liver disease will 
reach the age of 19 years with their native liver. These 
data highlight the need for age-related therapies that 
not only address ALGS-related cholestasis, but also 
those that target fibrogenesis and the development of 
portal hypertension.
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